Delivery Order SPE2DB22D3301-SPE2DB25FY3TN
- Not listed
- The U.S. Department of Defense's Medical Supply Chain awarded a $1,530.00 delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Fulvestrant 250 mg/5 mL syringes. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 2, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. The contract represents a single delivery order fulfillment under AmerisourceBergen's larger indefinite delivery contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Fulvestrant 250 mg/5 mL syringes with a ceiling value of $1,145.70. This non-set-aside, competitively awarded delivery order features firm fixed pricing and is scheduled for completion by August 8, 2025. The work will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Fulvestrant 250 mg/5 ml syringes valued at $3,592.57, with an ultimate completion date of December 11, 2025. This is a firm fixed price delivery order with no set-aside designation, issued on December 10, 2025. AmerisourceBergen will perform the work at its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $1,328.90 to AmerisourceBergen Drug Corp on December 9, 2025, for the supply of Fulvestrant 250 mg/5 ml syringes (5 ml quantity). The contract employs firm fixed pricing with a completion date of December 10, 2025, and represents a non-set-aside competitive award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location in the same municipality. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,509.60 to AmerisourceBergen Drug Corp for Fulvestrant 250 mg/5 ml syringes on December 10, 2025, with completion scheduled for December 11, 2025. This competitively awarded, firm fixed-price delivery order represents a small-value transaction for a specialized pharmaceutical product to be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation. This delivery...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Fulvestrant 250 mg/5 mL syringes (5 mL quantity) with a contract ceiling value of $1,224.00. This is a firm fixed-price delivery order with an ultimate completion date of July 31, 2025, and was awarded competitively without set-aside restrictions. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a major...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Fulvestrant 250 mg/5 ml syringes, a specialty medication, under a delivery order valued at $1,231.10. The contract has an ultimate completion date of December 27, 2024 and is a firm fixed-price delivery order. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $1,145.70, is for the supply of 4567954913 FULVESTRANT 250 MG/5 ML SYRING 5ML, a pharmaceutical product, with a period of performance through April 18, 2025. Amerisourcebergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which serves...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,060.00 firm-fixed-price contract is for the supply of 4567008677 - Fulvestrant 250 mg/5 ml syringes. The contract has a completion date of January 23, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- AmerisourceBergen Drug Corp was awarded a delivery order on July 22, 2025, by the Defense Logistics Agency's Medical Supply Chain to supply FULPHILA 6 mg/0.6 mL syringes with a contract value of $10,523.70. The delivery order is structured as a firm fixed price contract with no set-aside designation, indicating it was competitively awarded. Performance of this delivery order will be completed by July 23, 2025, at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB25FY3TNDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,370.92 to AmerisourceBergen Drug Corp for the supply of Fulvestrant 250 mg/5 mL syringes on April 23, 2025, with an ultimate completion date of April 24, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion comprehensive pharmaceutical supply vehicle running through December 2026. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement across the Defense Health Agency and military healthcare systems. The SPE2DX prime contract enables the company to supply a broad range of pharmaceutical products, specialty medications, vaccines, and medical supplies to support military healthcare programs globally. This specific delivery order for Fulvestrant, a hormone therapy medication, exemplifies the company's role in fulfilling federal medical supply requirements through the DLA's pharmaceutical distribution network.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 4/23/25 |